Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News Avacta (AIM: AVCT) sets 2026 clinical momentum with AVA6103 trial launch and AVA6000 data readouts Avacta targets dual clinical milestones in 2026 with AVA6103 trial launch and AVA6000 readouts. Find out how its small-molecule platform could reshape oncology. bySrinathJanuary 26, 2026